<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392339</url>
  </required_header>
  <id_info>
    <org_study_id>0985/08</org_study_id>
    <nct_id>NCT01392339</nct_id>
  </id_info>
  <brief_title>Obstructive Sleep Apnea and Genes Expression</brief_title>
  <acronym>HIP</acronym>
  <official_title>Sleep Apnea: Interface Between Basic and Clinical Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associacao Fundo de Incentivo a Psicofarmcologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Associacao Fundo de Incentivo a Psicofarmcologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea is a multi-component disease. This study will test the hypotheses
      that hypoxia per se modulates gene expression in animal model of sleep apnea and these
      results may be translated with alterations that occur in apneic patients. Thus, we aim to
      integrate basic and clinical research to shed light on novel candidate genes involved in
      sleep apnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-four male rats were exposed to chronic intermittent hypoxia (5% O2) or normoxia for 6
      wks. Following chronic intermittent hypoxia, a group of 8 rats were removed from the chronic
      intermittent hypoxia protocol and allowed to normoxic conditions over a period of 2 wks. For
      the clinical protocol, the AHI measured by overnight polysomnography will be use to select
      individuals with sleep-related breathing disorders, and controls (30-60 years, Body Mass
      Index (BMI) &lt; 35kg/m2). Moreover, the investigators will evaluate the subjective sleep
      parameters (sleep disorders questionnaire, the Epworth Sleepiness Scale, sleep diaries).
      After standard CPAP titration, men with severe obstructive sleep apnea will be assigned for
      the CPAP protocol for future assessment of the influence of 6 months obstructive sleep apnea
      treatment. A total of 84 genes are evaluated using the Hypoxia Signaling Pathway PCR Array
      (SA Biosciences, EUA).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea/Hypopnea Index</measure>
    <time_frame>6 months after the basal evaluation</time_frame>
    <description>Polysomnographic date of sleep stages percentages, sleep efficiency, arousals, apnea-hypopnea index, oxyhemoglobin saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expression</measure>
    <time_frame>6 months after the basal evaluation</time_frame>
    <description>A total of 84 genes are evaluated using the Hypoxia Signaling Pathway PCR Array (SA Biosciences, EUA), C-reactive protein (CRP), and biochemical parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure (CPAP)</intervention_name>
    <description>Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects aged between 30 and 60 years old

          -  Normal range of laboratory tests complete blood count (CBC), glucose, total
             cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very
             low-density lipoprotein (LDL), triglycerides

          -  Body Mass Index (BMI) &lt; 35kg/m2

        Exclusion Criteria:

          -  Presence of clinical diseases (chronic obstructive pulmonary disease, asthma,
             interstitial lung diseases, neuromuscular diseases, heart failure, thyroid disease,
             rheumatologic and psychiatric) and other sleep disorders

          -  Smoking status

          -  Participants who had current or historical treatment with CPAP or any other treatment
             for OSA

          -  Presence of anatomical obstructive upper airway, tonsil grade III and IV septal
             deviation and grade III (severe) that may affect the outcome of CPAP

          -  Alcoholism

          -  Use of sleep-inducing medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana C Perry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lia Rita A Bittencourt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Associacao Fundo de Incentivo a Psicofarmacologia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliana C Perry, PhD</last_name>
    <phone>55-11-8636-9979</phone>
    <email>julianaciniperry@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silverio A Garbuio, Master</last_name>
    <phone>55-11-8611-9251</phone>
    <email>silverio.garbuio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AFIP - Instituto do Sono (Sleep Institute)</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana C Perry, PhD</last_name>
      <phone>55-11-8636-9979</phone>
      <email>julianaciniperry@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Silverio A Garbuio, Master</last_name>
      <phone>55-11-8611-9251</phone>
      <email>silverio.garbuio@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Juliana C Perry, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lia Rita A Bittencourt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.sabiosciences.com/</url>
    <description>Hypoxia Signaling Pathway PCR Array (SA Biosciences, EUA)</description>
  </link>
  <link>
    <url>http://www.aasmnet.org/</url>
    <description>American Academy of Sleep Medicine</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lia Rita Azeredo Bittencourt</name_title>
    <organization>Associacao Fundo de Incentivo a Psicofarmacologia - AFIP</organization>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <keyword>CPAP</keyword>
  <keyword>hypoxia</keyword>
  <keyword>sleep</keyword>
  <keyword>translational science</keyword>
  <keyword>gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 11, 2012</submitted>
    <returned>May 7, 2012</returned>
    <submitted>May 28, 2012</submitted>
    <returned>July 20, 2012</returned>
    <submitted>October 26, 2012</submitted>
    <returned>November 26, 2012</returned>
    <submitted>January 29, 2013</submitted>
    <returned>March 7, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

